
Novo Nordisk has presented positive results from a phase III trial of its treatment for children with growth hormone deficiency, dubbed Sogroya, according to a company press release.
The data was made public today in connection with the Endocrine Society’s annual meeting, ENDO 2022, which is taking place in Georgia, US.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app